Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
Condition(s):Renal Cell CancerLast Updated:August 2, 2022Withdrawn
Hide Studies Not Open or Pending
Condition(s):Renal Cell CancerLast Updated:August 2, 2022Withdrawn
Condition(s):Difficulty in Sleep InitiationLast Updated:July 10, 2023Completed
Condition(s):Aging; Mitochondrial FunctionLast Updated:August 20, 2020Terminated
Condition(s):Autoimmune Polyglandular Syndrome Type I; Autoimmune KeratitisLast Updated:May 5, 2020Completed
Condition(s):Hepatic EncephalopathyLast Updated:October 11, 2017Unknown status
Condition(s):Sleep DisturbanceLast Updated:March 8, 2023Not yet recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:June 4, 2020Completed
Condition(s):Glioma of BrainLast Updated:December 29, 2022Recruiting
Condition(s):Muscle Protein SynthesisLast Updated:June 21, 2019Completed
Condition(s):Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH WHO Group ILast Updated:December 9, 2021Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.